AI辅助平台让临床数据清洗提速6倍且错误率下降6倍,节省数百万美元。
Leveraging AI to Accelerate Medical Data Cleaning: A Comparative Study of AI-Assisted vs. Traditional Methods
- 用大模型+医学规则结合,自动识别医疗数据问题。
- 清洗速度提升6.03倍,错误率从54.67%降至8.48%。
- 适合药企临床团队,显著降低研发成本与时间。
临床试验数据清洗是药物研发的关键瓶颈,传统人工审核难以应对数据量与复杂度的指数增长。本文提出Octozi AI辅助平台,融合大语言模型与领域专用规则,实现医学数据审查的自动化。在10名经验丰富的医学审阅员参与的对照实验中,AI辅助使数据清洗吞吐量提升6.03倍,错误率由54.67%降至8.48%(改善6.44倍),同时将误报查询减少15.48倍,减轻了研究机构负担。对代表性III期肿瘤试验的经济分析显示,可节省510万美元,主要来自数据库锁定提前5天(节约440万美元)、审阅效率提升(42万美元)及查询管理压力降低(28.8万美元)。该效果在不同经验水平审阅员间保持一致,表明其普适性。结果表明,AI辅助方法可有效解决临床试验运营中的根本低效问题,推动数据库锁定时间缩短33%,在保障合规的前提下大幅压缩研发成本。本研究为安全关键型临床流程引入AI提供了框架,展示了人机协同在制药临床试验中的变革潜力。
原文摘要 · Abstract (English)
Clinical trial data cleaning represents a critical bottleneck in drug development, with manual review processes struggling to manage exponentially increasing data volumes and complexity. This paper presents Octozi, an artificial intelligence-assisted platform that combines large language models with domain-specific heuristics to transform medical data review. In a controlled experimental study with experienced medical reviewers (n=10), we demonstrate that AI assistance increased data cleaning throughput by 6.03-fold while simultaneously decreasing cleaning errors from 54.67% to 8.48% (a 6.44-fold improvement). Crucially, the system reduced false positive queries by 15.48-fold, minimizing unnecessary site burden. Economic analysis of a representative Phase III oncology trial reveals potential cost savings of $5.1 million, primarily driven by accelerated database lock timelines (5-day reduction saving $4.4M), improved medical review efficiency ($420K savings), and reduced query management burden ($288K savings). These improvements were consistent across reviewers regardless of experience level, suggesting broad applicability. Our findings indicate that AI-assisted approaches can address fundamental inefficiencies in clinical trial operations, potentially accelerating drug development timelines such as database lock by 33% while maintaining regulatory compliance and significantly reducing operational costs. This work establishes a framework for integrating AI into safety-critical clinical workflows and demonstrates the transformative potential of human-AI collaboration in pharmaceutical clinical trials.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。